Cargando…

The therapeutic potential of RNA Polymerase I transcription inhibitor, CX-5461, in uterine leiomyosarcoma

Background. Uterine leiomyosarcoma is a rare aggressive smooth muscle cancer with poor survival rates. RNA Polymerase I (Pol I) activity is elevated in many cancers supporting tumour growth and prior studies in uterine leiomyosarcoma revealed enlarged nucleoli and upregulated Pol I activity-related...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kang, Chang-Won, Hannan, Katherine M., Blackburn, Anneke C., Loh, Amos H. P., Hong, Kuick Chik, Yuan, Goh Jian, Hein, Nadine, Drygin, Denis, Hannan, Ross D., Coupland, Lucy A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2022
Materias:	Preclinical Studies
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9098598/ https://www.ncbi.nlm.nih.gov/pubmed/35201535 http://dx.doi.org/10.1007/s10637-022-01222-w

Ejemplares similares

Targeting RNA Polymerase I Transcription Activity in Osteosarcoma: Pre-Clinical Molecular and Animal Treatment Studies
por: Kang, Chang-Won, et al.
Publicado: (2023)

Inhibition of RNA polymerase I transcription initiation by CX-5461 activates non-canonical ATM/ATR signaling
por: Quin, Jaclyn, et al.
Publicado: (2016)

rDNA Chromatin Activity Status as a Biomarker of Sensitivity to the RNA Polymerase I Transcription Inhibitor CX-5461
por: Son, Jinbae, et al.
Publicado: (2020)

CX-5461 induces radiosensitization through modification of the DNA damage response and not inhibition of RNA polymerase I
por: Lehman, Stacey L., et al.
Publicado: (2022)

The RNA polymerase I transcription inhibitor CX-5461 cooperates with topoisomerase 1 inhibition by enhancing the DNA damage response in homologous recombination-proficient high-grade serous ovarian cancer
por: Yan, Shunfei, et al.
Publicado: (2020)

CX-5461 activates the DNA damage response and demonstrates therapeutic efficacy in high-grade serous ovarian cancer
por: Sanij, Elaine, et al.
Publicado: (2020)

Therapeutic efficacy of the novel selective RNA polymerase I inhibitor CX‐5461 on pulmonary arterial hypertension and associated vascular remodelling
por: Xu, Xia, et al.
Publicado: (2021)

CX-5461 Treatment Leads to Cytosolic DNA-Mediated STING Activation in Ovarian Cancer
por: Cornelison, Robert, et al.
Publicado: (2021)

The Targeting of RNA Polymerase I Transcription Using CX-5461 in Combination with Radiation Enhances Tumour Cell Killing Effects in Human Solid Cancers
por: Ismael, Mohammed, et al.
Publicado: (2019)

Alternative splicing of human telomerase reverse transcriptase in gliomas and its modulation mediated by CX-5461
por: Li, Guihong, et al.
Publicado: (2018)

CX-5461 Inhibits Pancreatic Ductal Adenocarcinoma Cell Growth, Migration and Induces DNA Damage
por: El Hassouni, Btissame, et al.
Publicado: (2019)

CX-5461 can destabilize replication forks in PARP inhibitor-resistant models of ovarian cancer
por: Xuan, Jiachen, et al.
Publicado: (2020)

Ubiquitin-mediated DNA damage response is synthetic lethal with G-quadruplex stabilizer CX-5461
por: Masud, Tehmina, et al.
Publicado: (2021)

The chemotherapeutic agent CX-5461 irreversibly blocks RNA polymerase I initiation and promoter release to cause nucleolar disruption, DNA damage and cell inviability
por: Mars, Jean-Clément, et al.
Publicado: (2020)

The chemotherapeutic CX-5461 primarily targets TOP2B and exhibits selective activity in high-risk neuroblastoma
por: Pan, Min, et al.
Publicado: (2021)

CX-5461 is a DNA G-quadruplex stabilizer with selective lethality in BRCA1/2 deficient tumours
por: Xu, Hong, et al.
Publicado: (2017)

A transcriptional program associated with cell cycle regulation predominates in the anti-inflammatory effects of CX-5461 in macrophage
por: Wang, Jie, et al.
Publicado: (2022)

CX-5461 induces autophagy and inhibits tumor growth via mammalian target of rapamycin-related signaling pathways in osteosarcoma
por: Li, Leiming, et al.
Publicado: (2016)

CX-5461 Enhances the Efficacy of APR-246 via Induction of DNA Damage and Replication Stress in Triple-Negative Breast Cancer
por: Makhale, Ashwini, et al.
Publicado: (2021)

CX-5461 causes nucleolar compaction, alteration of peri- and intranucleolar chromatin arrangement, an increase in both heterochromatin and DNA damage response
por: Snyers, Luc, et al.
Publicado: (2022)

Uterine Leiomyosarcoma
por: Byar, Katherine L., et al.
Publicado: (2022)

Transient rRNA synthesis inhibition with CX-5461 is sufficient to elicit growth arrest and cell death in acute lymphoblastic leukemia cells
por: Negi, Sandeep S., et al.
Publicado: (2015)

Results of the phase I CCTG IND.231 trial of CX-5461 in patients with advanced solid tumors enriched for DNA-repair deficiencies
por: Hilton, John, et al.
Publicado: (2022)

rRNA synthesis inhibitor, CX-5461, activates ATM/ATR pathway in acute lymphoblastic leukemia, arrests cells in G2 phase and induces apoptosis
por: Negi, Sandeep S., et al.
Publicado: (2015)

Microvessels Density in Uterine Leiomyosarcoma
por: Bobiński, Marcin, et al.
Publicado: (2015)

The frequency and clinical significance of DNA polymerase beta (POLβ) expression in breast ductal carcinoma in situ (DCIS)
por: Al-Kawaz, Abdulbaqi, et al.
Publicado: (2021)

Distinctive outcome in patients with non-uterine and uterine leiomyosarcoma
por: Lamm, Wolfgang, et al.
Publicado: (2014)

Molecular Approach to Uterine Leiomyosarcoma: LMP2-Deficient Mice as an Animal Model of Spontaneous Uterine Leiomyosarcoma
por: Hayashi, Takuma, et al.
Publicado: (2011)

A G-quadruplex stabilizer, CX-5461 combined with two immune checkpoint inhibitors enhances in vivo therapeutic efficacy by increasing PD-L1 expression in colorectal cancer
por: Chung, Shin-Yi, et al.
Publicado: (2022)

Potential Biomarker for Human Uterine Leiomyosarcoma
por: Hayashi, Takuma, et al.
Publicado: (2014)

Uterine leiomyosarcoma: A case report
por: Kaur, Khushpreet, et al.
Publicado: (2014)

Prevalence and occult rates of uterine leiomyosarcoma
por: Wang, Lingxiang, et al.
Publicado: (2020)

A Case Report Of Uterine Leiomyosarcoma
por: Cao, Siyu, et al.
Publicado: (2019)

The Role of Hedgehog Pathway in Uterine Leiomyosarcoma
por: Garcia, Natalia, et al.
Publicado: (2021)

Perforated intestinal leiomyosarcoma as a metastasis of uterine leiomyosarcoma: a case report
por: Saylam, Barış, et al.
Publicado: (2009)

Cervical leiomyosarcoma in a teenage girl: A rare form of uterine leiomyosarcoma()
por: Adewole, Adebayo A., et al.
Publicado: (2021)

Health care professionals overestimate the risk for locoregional recurrences after breast cancer treatment depending on their specialty
por: Ankersmid, Jet W., et al.
Publicado: (2022)

Inhibition of Pol I Transcription a New Chance in the Fight Against Cancer
por: Hein, Nadine, et al.
Publicado: (2017)

The Ribosomal Gene Loci—The Power behind the Throne
por: Panov, Konstantin I., et al.
Publicado: (2021)

Vulvar Leiomyosarcomas: A Case Series with Clinical Comparison to Uterine Leiomyosarcomas and Review of the Literature
por: Verta, Stephanie, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_m8isgvkpvl58vf1j9e1lj86k7u